Clinical Judgment Versus Biomarker Prostate Cancer Gene 3: Which Is Best When Determining the Need for Repeat Prostate Biopsy?Bertrand Tombal, Herman Stoevelaar, Gerald L. Andriole et al.|Urology|2013Cited by 32
Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinionFranklin C. Lowe, Herman Stoevelaar, F. Desgrandchamps et al.|Prostate Cancer and Prostatic Diseases|2005Cited by 29
Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinionBertrand Tombal, Herman Stoevelaar, Filip Ameye et al.|World Journal of Urology|2011Cited by 19
Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertiseMark Speakman, Herman Stoevelaar, J.E. Batista et al.|Prostate Cancer and Prostatic Diseases|2005Cited by 13
Personalised versus non-individualised case-based CME: A randomised pilot studyHerman Stoevelaar, Martin C. Michel, Amit Bahl et al.|Journal of European CME|2022Cited by 1